Kakao's Profit Plunges on Higher Costs; Revenue Rises
By Kwanwoo Jun
South Korean mobile-internet platform giant Kakao's profit plunged due to higher operating costs for the July-September period despite solid revenue growth.
Kakao's third-quarter net profit fell 64% from a year earlier to 49.49 billion won ($37.8 million), it said Thursday. That missed a FactSet-compiled consensus forecast of KRW96.60 billion.
Revenue during the quarter rose 16% from a year earlier, while operating profit edged down 6.7% year-over-year, said the company, which operates South Korea's top mobile messaging app Kakao Talk.
Kakao attributed the net profit drop to increased business costs to cover artificial-intelligence investments, one-off labor expenses and higher corporate taxes.
Operating costs increased 18% from a year earlier in the September quarter, it said.
Sales of paid content rose sharply and platform-based advertisements sustained steady growth though advertising markets remained sluggish in South Korea, it added.
Kakao's shares were 0.6% higher in morning trade after the quarterly results.
Write to Kwanwoo Jun at kwanwoo.jun@wsj.com
(END) Dow Jones Newswires
November 08, 2023 21:54 ET (02:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track